Renal, Dialysis and Transplant Unit, Department of Emergency and Organ Transplantation, University of Bari, Bari, Italy.
Nephrol Dial Transplant. 2010 Dec;25(12):4071-7. doi: 10.1093/ndt/gfq377. Epub 2010 Jun 30.
The term chronic allograft nephropathy (CAN) was deleted in the Eighth Banff Classification and two new categories were introduced: chronic T-cell-mediated rejection (CTMR) and chronic active humoral rejection (CAHR). The aim of this study was to revise our CAN cases diagnosed in the last 4 years, analyse allograft survival rates and identify types of infiltrating cells in the different settings.
Seventy-nine patients with biopsy-proven CAN were examined and classified into four groups according to the Banff 2005 criteria: CTMR, CAHR, chronic calcineurin inhibitor toxicity (CNITOX) and interstitial fibrosis and tubular atrophy not otherwise specified (NOS). CD4, CD8, CD20, CD68, CD103, Foxp3 and IL-17 protein expression and C4d deposits were investigated.
We diagnosed 20 CTMR, 13 CAHR, 28 CNITOX, and 18 NOS. Death-censored graft survival at 4 years from renal biopsy was worse in CAHR compared with the other types of chronic injury. Glomerular CD8(+) cells were increased in CTMR vs CNITOX and NOS. Interstitial CD4(+) and CD8(+) cells were increased in CTMR vs CNITOX. CD68(+) cells in glomerular and peritubular capillaries were higher in CAHR vs CNITOX, CTMR and NOS. CD103(+) cells were higher in cases with tubulitis than in those without. T regulatory and T helper 17 cells were rarely observed in the different settings.
Graft survival was worse in patients with CAHR. The presence of any grade transplant glomerulopathy and chronic allograft vasculopathy are poorer prognostic factors. Infiltrating CD8(+), CD103(+) and CD4(+) cells may help to differentiate CTMR from other types of chronic injury, thus improving diagnostic/prognostic features of biopsy in patients with chronic allograft dysfunction.
慢性同种异体移植肾肾病(CAN)一词已在第八版 Banff 分类中被删除,并引入了两个新类别:慢性 T 细胞介导的排斥反应(CTMR)和慢性活跃体液排斥反应(CAHR)。本研究的目的是修订过去 4 年内我们诊断的 CAN 病例,分析移植物存活率并确定不同情况下浸润细胞的类型。
对 79 例经活检证实为 CAN 的患者进行检查,并根据 2005 年 Banff 标准分为四组:CTMR、CAHR、慢性钙调神经磷酸酶抑制剂毒性(CNITOX)和非特指的间质纤维化和肾小管萎缩(NOS)。检测 CD4、CD8、CD20、CD68、CD103、Foxp3 和 IL-17 蛋白表达及 C4d 沉积。
我们诊断出 20 例 CTMR、13 例 CAHR、28 例 CNITOX 和 18 例 NOS。与其他慢性损伤类型相比,CAHR 患者肾活检后 4 年死亡风险的无失访移植物存活率更差。与 CNITOX 和 NOS 相比,CTMR 患者肾小球 CD8(+)细胞增加。与 CNITOX 相比,CTMR 患者间质 CD4(+)和 CD8(+)细胞增加。与 CNITOX、CTMR 和 NOS 相比,CAHR 患者肾小球和肾小管毛细血管周围 CD68(+)细胞更高。存在小管炎的病例中 CD103(+)细胞更高。在不同情况下很少观察到 T 调节细胞和 T 辅助 17 细胞。
CAHR 患者的移植物存活率更差。任何等级的移植肾小球病和慢性同种异体血管病均为较差的预后因素。浸润性 CD8(+)、CD103(+)和 CD4(+)细胞可能有助于将 CTMR 与其他类型的慢性损伤区分开来,从而改善慢性移植物功能障碍患者活检的诊断/预后特征。